KNSA Stock Overview
A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KNSA from our risk checks.
Kiniksa Pharmaceuticals International, plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.96 |
| 52 Week High | US$27.92 |
| 52 Week Low | US$14.12 |
| Beta | 0.33 |
| 11 Month Change | -11.46% |
| 3 Month Change | 28.33% |
| 1 Year Change | 37.54% |
| 33 Year Change | 110.36% |
| 5 Year Change | 219.47% |
| Change since IPO | 23.06% |
Recent News & Updates
Recent updates
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Shareholder Returns
| KNSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | -3.8% | 1.8% |
| 1Y | 37.5% | 16.5% | 31.9% |
Return vs Industry: KNSA exceeded the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: KNSA exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| KNSA volatility | |
|---|---|
| KNSA Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNSA has not had significant price volatility in the past 3 months.
Volatility Over Time: KNSA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 297 | Sanj Patel | www.kiniksa.com |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc Fundamentals Summary
| KNSA fundamental statistics | |
|---|---|
| Market cap | US$1.72b |
| Earnings (TTM) | -US$10.23m |
| Revenue (TTM) | US$338.93m |
5.0x
P/S Ratio-166.9x
P/E RatioIs KNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNSA income statement (TTM) | |
|---|---|
| Revenue | US$338.93m |
| Cost of Revenue | US$126.64m |
| Gross Profit | US$212.29m |
| Other Expenses | US$222.52m |
| Earnings | -US$10.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 62.63% |
| Net Profit Margin | -3.02% |
| Debt/Equity Ratio | 0% |
How did KNSA perform over the long term?
See historical performance and comparison